These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11733960)

  • 1. Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma.
    Sakuragi N; Hirai A; Tada M; Yamada H; Yamamoto R; Fujimoto S; Moriuchi T
    Gynecol Oncol; 2001 Dec; 83(3):485-90. PubMed ID: 11733960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.
    Jia L; Liu Y; Yi X; Miron A; Crum CP; Kong B; Zheng W
    Clin Cancer Res; 2008 Apr; 14(8):2263-9. PubMed ID: 18369088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular carcinogenesis of endometrial cancer.
    Liu FS
    Taiwan J Obstet Gynecol; 2007 Mar; 46(1):26-32. PubMed ID: 17389185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer.
    Hassan NM; Tada M; Hamada J; Kashiwazaki H; Kameyama T; Akhter R; Yamazaki Y; Yano M; Inoue N; Moriuchi T
    Cancer Lett; 2008 Oct; 270(1):108-19. PubMed ID: 18555592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
    Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
    Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
    Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease.
    Kupryjanczyk J; Thor AD; Beauchamp R; Poremba C; Scully RE; Yandell DW
    Mod Pathol; 1996 Mar; 9(3):166-73. PubMed ID: 8685209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.
    Marutani M; Tonoki H; Tada M; Takahashi M; Kashiwazaki H; Hida Y; Hamada J; Asaka M; Moriuchi T
    Cancer Res; 1999 Oct; 59(19):4765-9. PubMed ID: 10519380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
    Hu WF; Liu MQ; Zhao Q
    Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
    Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
    Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Endometrial carcinoma and precursor lesions].
    Djordjević B; Stanojević Z
    Srp Arh Celok Lek; 2007; 135(3-4):230-4. PubMed ID: 17642468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 tumor suppressor gene mutation in ovarian cancer in Thai patients.
    Neungton N; Neungton S; Leelaphatanadit C; Dangrat C; Soiampornkul R
    J Med Assoc Thai; 2002 Jun; 85(6):658-67. PubMed ID: 12322838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of yeast functional assay to detect p53 gene mutation in minute endoscopic samples of colonic mucosal neoplasia].
    Nakamura Y
    Hokkaido Igaku Zasshi; 1998 Sep; 73(5):505-17. PubMed ID: 9846280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection and sequence analysis of the p53 gene mutation in epithelial ovarian cancer].
    Guan X; Lang J; Bian M
    Zhonghua Fu Chan Ke Za Zhi; 1998 Mar; 33(3):165-7. PubMed ID: 10682487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.
    Sobel G; Németh J; Kiss A; Lotz G; Szabó I; Udvarhelyi N; Schaff Z; Páska C
    Gynecol Oncol; 2006 Nov; 103(2):591-8. PubMed ID: 16797678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
    Lax SF
    Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors.
    Pfister C; Flaman JM; Martin C; Grise P; Frebourg T
    J Urol; 1999 Jun; 161(6):1973-5. PubMed ID: 10332483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer.
    Sakuragi N; Watari H; Ebina Y; Yamamoto R; Steiner E; Koelbl H; Yano M; Tada M; Moriuchi T
    Int J Cancer; 2005 Sep; 116(4):514-9. PubMed ID: 15825182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.